The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 31, 2020

Filed:

Oct. 25, 2016
Applicant:

Kirin Holdings Kabushiki Kaisha, Nakano-ku, Tokyo, JP;

Inventors:

Hiroaki Suzuki, Tokyo, JP;

Kenta Jounai, Tokyo, JP;

Daisuke Fujiwara, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/747 (2015.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01); A23L 33/135 (2016.01); C12N 1/20 (2006.01); A61K 39/145 (2006.01); A61K 39/02 (2006.01); C12N 7/00 (2006.01); A61K 9/00 (2006.01); A61K 35/00 (2006.01); A23L 33/10 (2016.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A23L 33/10 (2016.08); A23L 33/135 (2016.08); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); A61K 35/747 (2013.01); A61K 39/00 (2013.01); A61K 39/02 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); C12N 1/20 (2013.01); C12N 7/00 (2013.01); A23V 2002/00 (2013.01); A23Y 2240/41 (2013.01); A61K 2035/115 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55594 (2013.01); A61K 2039/575 (2013.01); C12N 2760/16034 (2013.01); C12N 2760/16071 (2013.01); Y02A 50/403 (2018.01);
Abstract

Provided are a composition and a food or drink, having the effect of enhancing an immune response to an antigen, which is administered by another route such as subcutaneous injection, by orally administering to a subject, lactic acid bacteria, a culture thereof, a treated product thereof, or a composition comprising the same. An oral ingestion composition, which comprises a lactic acid bacterium strain that issubsp.enhancing the proliferation of cytotoxic T lymphocytes (CTL) and the generation of antibodies, or a culture or treated product thereof, and is used in combination with an antigen as a vaccine, wherein the oral ingestion composition is for use in enhancing the proliferation of cytotoxic T lymphocytes (CTL) specific to the antigen and the generation of antibodies specific to the antigen.


Find Patent Forward Citations

Loading…